Innovent Biologics First Half 2025 Earnings: EPS: CN¥0.51 (vs CN¥0.24 loss in 1H 2024)

Innovent Biologics (HKG:1801) First Half 2025 Results

Key Financial Results

• Revenue: CN¥5.95b (up 51% from 1H 2024).
• Net income: CN¥834.3m (up from CN¥392.6m loss in 1H 2024).
• Profit margin: 14% (up from net loss in 1H 2024).
• EPS: CN¥0.51 (up from CN¥0.24 loss in 1H 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Innovent Biologics Earnings Insights

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 8.7% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Innovent Biologics you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.